GlassScriptPhysician profile
Manuel C Aguilera
NPI 1114015500
$30,008.50
in general payments reported to CMS, 2019-2025
44 companies · $2,330 in 2025
The $2,330 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,487 · 2020: $4,111 · 2021: $7,099 · 2022: $5,686 · 2023: $3,582 · 2024: $3,713 · 2025: $2,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,613 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,613.47 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,070.78 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $4,079.06 | 2019-2025 | Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $1,853.70 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,650.99 | 2019-2024 | |
| Glaxosmithkline, LLC. | $1,635.18 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $1,424.16 | 2019-2025 | Tepezza, Krystexxa, Repatha |
| Amarin Pharma, INC. | $1,315.91 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,199.70 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $1,119.65 | 2020-2025 | Nexletol |
| Lilly USA, LLC | $1,110.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $983.68 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Astellas Pharma US INC | $816.36 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $763.71 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $657.58 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $621.37 | 2019-2023 | Camzyos, Eliquis |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Aguilera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.